Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors

The NADPH oxidase 2 (NOX2) complex is a professional producer of reactive oxygen species (ROS) and is mainly expressed in phagocytes. While the activity of the NOX2 complex is essential for immunity against pathogens and protection against autoimmunity, its role in the development of malignant tumor...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 12; p. e84148
Main Authors Kelkka, Tiina, Pizzolla, Angela, Laurila, Juha Petteri, Friman, Tomas, Gustafsson, Renata, Källberg, Eva, Olsson, Olof, Leanderson, Tomas, Rubin, Kristofer, Salmi, Marko, Jalkanen, Sirpa, Holmdahl, Rikard
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 16.12.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The NADPH oxidase 2 (NOX2) complex is a professional producer of reactive oxygen species (ROS) and is mainly expressed in phagocytes. While the activity of the NOX2 complex is essential for immunity against pathogens and protection against autoimmunity, its role in the development of malignant tumors remains unclear. We compared wild type and Ncf1 (m1J) mutated mice, which lack functional NOX2 complex, in four different tumor models. Ncf1 (m1J) mutated mice developed significantly smaller tumors in two melanoma models in which B16 melanoma cells expressing a hematopoietic growth factor FLT3L or luciferase reporter were used. Ncf1 (m1J) mutated mice developed significantly fewer Lewis Lung Carcinoma (LLC) tumors, but the tumors that did develop, grew at a pace that was similar to the wild type mice. In the spontaneously arising prostate carcinoma model (TRAMP), tumor growth was not affected. The lack of ROS-mediated protection against tumor growth was associated with increased production of immunity-associated cytokines. A significant increase in Th2 associated cytokines was observed in the LLC model. Our present data show that ROS regulate rejection of the antigenic B16-luc and LLC tumors, whereas the data do not support a role for ROS in growth of intrinsically generated tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: RH SJ MS KR TL. Performed the experiments: TK AP JPL TF RG EK OO. Analyzed the data: TK AP JPL TF RG EK OO. Wrote the manuscript: TK RH SJ MS KR TL AP JPL TF RG EK OO.
Current address: Hematology Research Unit Helsinki, Biomedicum Helsinki, Division of Hematology, Department of Medicine, Helsinki, Finland
Current address: Department of Immunology, Monash University, Melbourne, Australia
Current address: Sanford Burnham Medical Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0084148